Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04038619 · ClinicalTrials.gov registry record · Phase 1

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT04038619: Recruiting Phase 1 study of Breast Cancer and Lung Cancer, sponsored by M.D. Anderson Cancer Center.

NCT04038619 is a Phase 1 study of Breast Cancer and Lung Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04038619, a Phase 1 study of Breast Cancer and Lung Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.

Primary Outcome

Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5. All events are recorded with grade and attribution to FMT.

Interventions

  • PROCEDURE Fecal Microbiota Transplantation
  • DRUG Loperamide

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-02-01
Est. Completion 2027-12-31
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What NCT04038619 shows while recruiting

NCT04038619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fecal Microbiota Transplantation is the first listed.

NCT04038619 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04038619 about?

NCT04038619 is a clinical study titled "Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients". This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effecti...

What is the current status of trial NCT04038619?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-02-01. Estimated completion is 2027-12-31.

What conditions does trial NCT04038619 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Ovarian Cancer, Melanoma, Cervical Cancer.

What interventions are being tested in trial NCT04038619?

The interventions under investigation include: Fecal Microbiota Transplantation (PROCEDURE), Loperamide (DRUG).

Who is sponsoring clinical trial NCT04038619?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04038619 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04038619's enrollment target sits among peer trials

40 876th of 1224 higher than 325 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04038619, the US trial registry maintained by the National Library of Medicine. NCT04038619 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.